CD44 and head and neck cancer: In particular, 500 kDa HA via CD44 activated downstream RhoC and Rho associated kinase (ROK) in HSC-3 head and neck cancer cells and promoted cell growth, invasion, migration and resistance to cisplatin [74,76].